Show simple item record

dc.contributor.authorSasamoto, Naoko
dc.contributor.authorBabic, Ana
dc.contributor.authorRosner, Bernard A.
dc.contributor.authorFortner, Renée T.
dc.contributor.authorVitonis, Allison F
dc.contributor.authorYamamoto, Hidemi
dc.contributor.authorFichorova, Raina N.
dc.contributor.authorTitus, Linda J.
dc.contributor.authorTjønneland, Anne
dc.contributor.authorHansen, Louise
dc.contributor.authorKvaskoff, Marina
dc.contributor.authorFournier, Agnès
dc.contributor.authorMancini, Francesca Romana
dc.contributor.authorBoeing, Heiner
dc.contributor.authorTrichopoulou, Antonia
dc.contributor.authorPeppa, Eleni
dc.contributor.authorKarakatsani, Anna
dc.contributor.authorPalli, Domenico
dc.contributor.authorGrioni, Sara
dc.contributor.authorMattiello, Amalia
dc.contributor.authorTumino, Rosario
dc.contributor.authorFiano, Valentina
dc.contributor.authorOnland-Moret, N. Charlotte
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorGram, Inger Torhild
dc.contributor.authorQuirós, José Ramón
dc.contributor.authorLujan-Barroso, Leila
dc.contributor.authorSánchez, María-José
dc.contributor.authorColorado-Yohar, Sandra
dc.contributor.authorBarricarte, Aurelio
dc.contributor.authorAmiano, Pilar
dc.contributor.authorIdahl, Annika
dc.contributor.authorLundin, Eva
dc.contributor.authorSartor, Hanna
dc.contributor.authorKhaw, Kay-Tee
dc.contributor.authorKey, Timothy J.
dc.contributor.authorMuller, David
dc.contributor.authorRiboli, Elio
dc.contributor.authorGunter, Marc
dc.contributor.authorDossus, Laure
dc.contributor.authorTrabert, Britton
dc.contributor.authorWentzensen, Nicolas
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorCramer, Daniel W.
dc.contributor.authorTworoger, Shelley S.
dc.contributor.authorTerry, Kathryn L.
dc.date.accessioned2020-02-27T07:03:43Z
dc.date.available2020-02-27T07:03:43Z
dc.date.issued2019-11-26
dc.description.abstract<i>Background</i> - Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. However, CA125 has been limited by low sensitivity and specificity in part due to normal variation between individuals. Personal characteristics that influence CA125 could be used to improve its performance as screening biomarker.<p><p> <i>Methods</i> - We developed and validated linear and dichotomous (≥35 U/mL) circulating CA125 prediction models in postmenopausal women without ovarian cancer who participated in one of five large population-based studies: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, <i>n</i> = 26,981), European Prospective Investigation into Cancer and Nutrition (EPIC, <i>n</i> = 861), the Nurses’ Health Studies (NHS/NHSII, <i>n</i> = 81), and the New England Case Control Study (NEC, <i>n</i> = 923). The prediction models were developed using stepwise regression in PLCO and validated in EPIC, NHS/NHSII and NEC.<p><p> <i>Result</i> - The linear CA125 prediction model, which included age, race, body mass index (BMI), smoking status and duration, parity, hysterectomy, age at menopause, and duration of hormone therapy (HT), explained 5% of the total variance of CA125. The correlation between measured and predicted CA125 was comparable in PLCO testing dataset (r = 0.18) and external validation datasets (r = 0.14). The dichotomous CA125 prediction model included age, race, BMI, smoking status and duration, hysterectomy, time since menopause, and duration of HT with AUC of 0.64 in PLCO and 0.80 in validation dataset.<p><p> <i>Conclusions</i> - The linear prediction model explained a small portion of the total variability of CA125, suggesting the need to identify novel predictors of CA125. The dichotomous prediction model showed moderate discriminatory performance which validated well in independent dataset. Our dichotomous model could be valuable in identifying healthy women who may have elevated CA125 levels, which may contribute to reducing false positive tests using CA125 as screening biomarker.en_US
dc.identifier.citationSasamoto N, Babic A, Rosner BA, Fortner RT, Vitonis AF, Yamamoto H, Fichorova RN, Titus, Tjønneland A, Hansen, Kvaskoff M, Fournier A, Mancini FR, Boeing H, Trichopoulou A, Peppa E, Karakatsani A, Palli D, Grioni S, Mattiello A, Tumino R, Fiano V, Onland-Moret NC, Weiderpass E, Gram IT, Quirós JR, Lujan-Barroso L, Sánchez M, Colorado-Yohar S, Barricarte A, Amiano P, Idahl A, Lundin E, Sartor H, Khaw K, Key TJ, Muller D, Riboli E, Gunter M, Dossus L, Trabert B, Wentzensen N, Kaaks R, Cramer DW, Tworoger SS, Terry KL. Development and validation of circulating CA125 prediction models in postmenopausal women. Journal of Ovarian Research. 2019;12:116:1-12en_US
dc.identifier.cristinIDFRIDAID 1796811
dc.identifier.doi10.1186/s13048-019-0591-4
dc.identifier.issn1757-2215
dc.identifier.urihttps://hdl.handle.net/10037/17519
dc.language.isoengen_US
dc.publisherBMCen_US
dc.relation.journalJournal of Ovarian Research
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/DG-SANCO/?/EU/?/?/en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2019 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleDevelopment and validation of circulating CA125 prediction models in postmenopausal womenen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record